secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001728117-25-000069
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Bio Q2 net loss $38.3M; PROSERA Phase 3 topline due Feb 2026
---------------------------------------------------------------------

- Net loss $38.3M ($0.17 per share) vs net income $49.2M in Q2 2024, driven by $88.8M one-time license revenue in prior year.
- Cash, equivalents and marketable securities $212.9M as of June 30, 2025; runway into 2027.
- PROSERA Phase 3 PAH study enrolled 390 patients; topline results expected February 2026.
- SERANATA Phase 3 PH-ILD study first site activations planned Q4 2025; 480-patient, 24-week trial.
- Collaboration revenue $11.5M (mostly cost reimbursement from Chiesi) vs $95.8M in Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811725000069/0001728117-25-000069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811725000069/goss-20250805.htm
  HTML page:      https://secwatch.observer/filing/0001728117-25-000069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer